By Lina carolina 
Researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, have identified a protein marker, CD74, that could revolutionize immunotherapy treatment for bowel cancer. This groundbreaking discovery, published in the esteemed journal Cancer Cell, suggests that measuring CD74 levels could accurately predict which patients are most likely to respond to immunotherapy, potentially opening the door for hundreds of individuals who were previously deemed ineligible for this life-saving treatment.
Bowel cancer, a formidable foe, stands as the fourth most prevalent cancer in the United Kingdom and the second leading cause of cancer-related mortality. Its complex nature is broadly categorized into two subtypes: the deficient subtype, characterized by missing or impaired DNA repair proteins, and the proficient subtype, where this DNA repair machinery remains intact. While cancer immunotherapies, designed to harness the patient’s own immune system to combat malignant cells, have transformed the treatment landscape for the deficient subtype, their efficacy remains limited. These revolutionary drugs benefit only about half of eligible patients. More critically, individuals with the proficient subtype, representing a staggering 90% of all bowel cancer cases, have historically been excluded from immunotherapy options due to a lack of predictive biomarkers. This new research, however, offers a beacon of hope, suggesting that the proficient subtype may not be entirely unresponsive after all.
Unraveling the Immune Microenvironment’s Role in Treatment Response
The research team embarked on an ambitious journey to dissect the intricate reasons behind immunotherapy’s variable success rates and to devise strategies for broadening patient eligibility. Their investigation meticulously examined the immune cells residing in the vicinity of different tumor types, recognizing their pivotal role in dictating a patient’s response to immunotherapy. By analyzing samples from both deficient and proficient subtypes, and comparing individuals who responded to immunotherapy with those who did not, the scientists gained crucial insights.
A key finding emerged: the presence and interaction of three specific types of immune cells were essential for a tumor to respond to treatment. These included cytotoxic T cells and Natural Killer (NK) cells, often referred to as "fighter cells" due to their direct role in eliminating cancer cells, and macrophages. Macrophages act as crucial scouts, displaying molecular "flags" on their surface to alert the body to the presence of threats, including cancerous invaders.
When these three immune cell populations were found to be present and in close proximity to cancer cells, a critical signaling cascade was initiated. The T cells released potent signaling molecules called interferons. These interferons, in turn, triggered a distinct signal within macrophages and tumor cells. This signaling pathway was notably more robust in deficient subtype tumors that successfully responded to immunotherapy. However, in a surprising turn of events, the researchers observed that a subset of patients within the proficient subtype also exhibited a comparable signaling intensity. This observation strongly suggested that, contrary to previous assumptions, some individuals with the proficient subtype might possess an immune system primed for a positive response to immunotherapy.
CD74: A Predictive Biomarker Emerges
Driven by the quest for a straightforward clinical tool to ascertain whether a patient’s immune system was optimally poised for immunotherapy success, the team turned their attention to identifying a specific molecular indicator. Employing a sophisticated, cutting-edge technique known as spatial transcriptomics, they were able to visualize and analyze the cellular and molecular landscape of tumors with unprecedented detail. This advanced methodology revealed that stimulated T cells were prompting nearby macrophages and tumor cells to produce a protein subsequently identified as CD74. Crucially, tumors that were responding favorably to immunotherapy drugs demonstrated significantly higher levels of CD74 expression.
To rigorously validate the potential of CD74 as a clinical predictor, the researchers expanded their investigation to include samples from several international clinical trials. These trials specifically focused on patients with the proficient subtype who were undergoing immunotherapy. The results were compelling: individuals who exhibited a positive response to immunotherapy consistently displayed significantly elevated levels of CD74 compared to those who did not respond. This finding strongly suggests that measuring CD74 levels could serve as a reliable predictor of immunotherapy response, irrespective of the patient’s bowel cancer subtype.
Implications for Clinical Practice and Patient Access
The ramifications of this discovery are profound. By identifying CD74 as a potential biomarker, clinicians may soon be able to identify individuals with the proficient subtype, who currently represent the vast majority of bowel cancer patients ineligible for immunotherapy, as potential candidates for this treatment. This could translate into a substantial increase in the number of patients benefiting from a highly effective therapeutic modality.
Francesca Ciccarelli, Principal Group Leader of the Cancer Systems Biology Laboratory at the Crick and Professor of Cancer Genomics at Queen Mary University of London’s Barts Cancer Institute, articulated the significance of the findings. "Immunotherapy drugs can be hugely successful for people with bowel cancer, but currently the majority of patients can’t be prescribed these drugs and, even when patients are eligible, we don’t know upfront who will respond," she stated. "Our work suggests that testing for CD74 levels — which signal that the immune system is ‘just right’ to fight the tumour — could widen access to immunotherapy. This could revolutionise treatment for a sizeable fraction of people with the proficient bowel cancer subtype, which is a large number of patients across the UK in real terms. It could also be used to identify people with the deficient subtype who won’t respond, saving them from experiencing side effects unnecessarily."
The dual benefit of CD74 as a predictive marker is a critical aspect of this research. Not only could it identify new responders, but it could also help avoid unnecessary treatment and associated side effects for those unlikely to benefit. This personalized approach to cancer therapy is at the forefront of modern oncology.
Kalum Clayton, a former postdoc at the Crick and joint first author of the study, alongside Pietro Andrei and Amelia Acha, highlighted the power of advanced scientific methodologies. "Our work shows how state-of-the-art technologies coupled with computational analysis can address important clinical questions," he remarked. "As an early career research scientist, seeing the potential of our work to provide benefit to patients and their families is greatly rewarding." This sentiment underscores the deep motivation driving scientific discovery – the ultimate aim of improving human health.
The Road to Clinical Implementation and Future Research
The research team is not resting on their laurels. They are actively collaborating with Cancer Research Horizons, an organization dedicated to translating scientific discoveries into clinical applications, to develop a diagnostic test that can be reliably implemented in clinical settings. This crucial step will involve rigorous validation and regulatory approval processes.
Beyond the immediate goal of a diagnostic test, the researchers are also delving deeper into the underlying biological mechanisms. They aim to understand precisely why macrophages and tumor cells overexpress CD74 in the context of an effective immune response. Furthermore, they plan to investigate whether this promising marker is also present and predictive in other types of cancer, potentially extending its clinical utility even further.
Anna Kinsella, Science Engagement Manager at Cancer Research UK, emphasized the broader significance of such fundamental research. "Immunotherapy treatments, such as immune checkpoint inhibitors, use the power of the immune system to fight cancer. Whilst these treatments benefit some people with bowel cancer, they aren’t effective for everyone," she explained. "Although further research is needed, studies like this — diving deep into the biology of tumours — help researchers find ways to predict when immunotherapy is likely to work. In the future, this could help clinicians tailor treatment and allow more people with bowel cancer to benefit from immunotherapy."
Kinsella continued, "Understanding the biology of cancer is vital to unlocking better ways to prevent, detect and treat it, so that people can live longer, better lives free from the fear of cancer. That’s why at Cancer Research UK, discovery research is at the heart of everything we do." This statement underscores the vital role of foundational scientific inquiry in driving progress against complex diseases like cancer.
The collaborative nature of this research is also noteworthy, with contributions from institutions including UCL, the University of Pisa, King’s College London, the Sarah Cannon Research Institute, and the Veneto Institute of Oncology. Such multi-institutional efforts are often crucial for tackling complex scientific challenges and accelerating the pace of discovery.
Context and Broader Impact
The development of effective immunotherapies represents one of the most significant advancements in cancer treatment over the past decade. These therapies, by modulating the immune system, have offered new hope for patients with previously intractable cancers. However, the challenge of patient selection has been a persistent hurdle. For bowel cancer, the dichotomy between the deficient and proficient subtypes has created a clear divide in treatment accessibility. The identification of CD74 as a biomarker that transcends this subtype classification is therefore a monumental step forward.
Historically, treatment decisions for bowel cancer have relied on factors such as tumor stage, grade, and the presence of specific genetic mutations. While these factors remain important, the integration of predictive biomarkers like CD74 promises to usher in an era of truly personalized medicine, where treatments are tailored to the individual biological characteristics of a patient’s tumor and their immune system’s capacity to respond.
The potential impact on public health is substantial. With bowel cancer being a leading cause of cancer death in the UK, expanding access to effective treatments could lead to a significant reduction in mortality rates. Furthermore, by avoiding ineffective treatments and their associated side effects, patients can experience improved quality of life and reduced healthcare costs.
The timeline for this research likely spans several years, from initial hypothesis generation and experimental design, through meticulous data collection and analysis, to publication and the subsequent stages of translational development. The publication in Cancer Cell signifies a rigorous peer-review process, indicating the high quality and scientific merit of the findings. The current phase, focused on developing a clinical test and further biological investigation, represents the critical transition from bench to bedside.
In conclusion, the discovery of CD74 as a predictive biomarker for immunotherapy response in bowel cancer is a landmark achievement. It exemplifies the power of scientific inquiry to address unmet clinical needs and offers a tangible pathway to improving the lives of countless patients. The ongoing work to translate these findings into a clinical tool holds immense promise for the future of cancer treatment.
